Precursors T Cell + Limited by the Number of CD 8 an Antitumor Response , but Efficacy Is CD 4-Directed Peptide Vaccination Augments
暂无分享,去创建一个
P. Allen | Matsui | L. Norian | Silvia S Kang | Leigh A. O’Mara | H. L. Hanson | L. O’Mara
[1] M. Bevan,et al. Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.
[2] Hao Shen,et al. Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.
[3] Vladimir Brusic,et al. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Martin A. Nowak,et al. Compromised Influenza Virus-Specific CD8+-T-Cell Memory in CD4+-T-Cell-Deficient Mice , 2002, Journal of Virology.
[5] B. Rocha,et al. A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory , 2002, Science.
[6] S. H. van der Burg,et al. Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.
[7] J. Sidney,et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. , 2002, Cancer research.
[8] Francesco M Marincola,et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.
[9] F. Marincola,et al. Functional Heterogeneity of Vaccine-Induced CD8+ T Cells1 , 2002, The Journal of Immunology.
[10] G. Schuler,et al. Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.
[11] M. Cheever,et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] J. Xiang,et al. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. , 2002, Cancer research.
[13] G. Belz,et al. Cutting Edge: Precursor Frequency Affects the Helper Dependence of Cytotoxic T Cells1 , 2002, The Journal of Immunology.
[14] A. Ribas,et al. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. , 2001, Cancer research.
[15] P. Coulie,et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[16] Steven A. Rosenberg,et al. Progress in human tumour immunology and immunotherapy , 2001, Nature.
[17] S. Schoenberger,et al. Stimulation via CD40 can substitute for CD4 T cell function in preventing reactivation of a latent herpesvirus , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] G. Zeng,et al. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. , 2001, Journal of immunotherapy.
[19] J. Trapani,et al. A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.
[20] P. Srivastava,et al. The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Speiser,et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] K. Knutson,et al. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.
[23] G. Zeng. MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design. , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[24] B. Robinson,et al. Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1 , 2000, The Journal of Immunology.
[25] B. Fox,et al. Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy1 , 2000, The Journal of Immunology.
[26] F. Marincola,et al. Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells , 2000, The Journal of Immunology.
[27] R. Schreiber,et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.
[28] O. Tsitsilonis,et al. Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor , 2000, The Journal of Immunology.
[29] Steven A. Rosenberg,et al. Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice , 2000, The Journal of Immunology.
[30] D. Pardoll,et al. Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes , 2000, The Journal of experimental medicine.
[31] S. Rosenberg,et al. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. , 1999, Cancer research.
[32] A. Enk,et al. Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.
[33] S. Steinberg,et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.
[34] R. Schreiber,et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .
[35] S. Rosenberg,et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.
[36] J. Shabanowitz,et al. Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.
[37] J. Altman,et al. Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.
[38] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[39] Polly Matzinger,et al. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.
[40] Richard A. Flavell,et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.
[41] Stephen P. Schoenberger,et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.
[42] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[43] C. Melief,et al. Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.
[44] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[45] A. Bernheim,et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. , 1998, Blood.
[46] D. Hanahan,et al. Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.
[47] W. Heath,et al. Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.
[48] R. Flavell,et al. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand , 1995, Nature.
[49] P. Monach,et al. A unique tumor antigen produced by a single amino acid substitution. , 1995, Immunity.
[50] R. Schwartz,et al. A subset of CD4+ thymocytes selected by MHC class I molecules. , 1994, Science.
[51] H. Pircher,et al. Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice , 1991, Cell.
[52] P. Allen,et al. T cell recognition of bovine ribonuclease. Self/non-self discrimination at the level of binding to the I-Ak molecule. , 1988, Journal of immunology.
[53] M. Bevan,et al. Introduction of soluble protein into the class I pathway of antigen processing and presentation , 1988, Cell.
[54] P. Allen,et al. Direct evidence for functional self-protein/Ia-molecule complexes in vivo. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[55] B. Kyewski,et al. CD4+ helper T cells are required for resistance to a highly metastatic murine tumor , 1987, European journal of immunology.
[56] Alessandro Sette,et al. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells , 1987, Nature.
[57] E. Unanue,et al. Differential requirements for antigen processing by macrophages for lysozyme-specific T cell hybridomas. , 1984, Journal of immunology.
[58] A. Deleo,et al. Mouse. I. Murine leukemia virus-related antigens and allo- antigens on cultured fibroblasts and sarcoma cells. Description of a unique antigen on balb/c meth a sarcoma. , 1977 .